Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.17 USD
Change Today +0.02 / 1.74%
Volume 238.8K
DSCO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

discovery laboratories inc (DSCO) Key Developments

Discovery Laboratories, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Discovery Laboratories Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported a net loss of $10.6 million or $0.15 per diluted share compared to a net loss of $11.7 million or $0.16 per basic and diluted share for the same period a year ago. Operating loss was $11,226,000 compared to $10,265,000 last year. Net cash outflows for the quarter ended December 31, 2014 were $10.2 million. Total revenue was $1,184,000 compared to $74,000 last year. For the year, the company reported a net loss of $44,058,000 or $0.56 per diluted share compared to a net loss of $45,215,000 or $0.82 per basic and diluted share for the same period a year ago. Operating loss was $43,258,000 compared to $44,508,000 last year. Total revenue was $2,835,000 compared to $388,000 last year.

Discovery Laboratories Inc. to Report Q4, 2014 Results on Mar 17, 2015

Discovery Laboratories Inc. announced that they will report Q4, 2014 results at 12:30 PM, GMT Standard Time on Mar 17, 2015

Discovery Laboratories Inc., Q4 2014 Earnings Call, Mar 17, 2015

Discovery Laboratories Inc., Q4 2014 Earnings Call, Mar 17, 2015

Discovery Laboratories Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Operating Cash Outflows Guidance for the Fourth Quarter of 2014

Discovery Laboratories Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $527,000 compared to $60,000 a year ago. Operating loss was $10,327,000 compared to $10,813,000 a year ago. Net loss was $11,324,000 or $0.13 per basic and diluted share compared to $12,224,000 or $0.22 per basic and diluted share a year ago. Net cash outflows before financing activities for the quarter ended September 30, 2014 were $10.6 million. For the nine months period, the company reported total revenue of $1,651,000 compared to $315,000 a year ago. Operating loss was $32,032,000 compared to $34,242,000 a year ago. Net loss was $33,423,000 or $0.41 per diluted share compared to $33,486,000 or $0.69 per diluted share a year ago. For the fourth quarter of 2014, the company anticipates operating cash outflows before financing activities of approximately $11 million.

Discovery Laboratories Inc. Announces Executive Changes

Discovery Laboratories Inc. announced organizational changes to the development leadership team and a special advisory appointment to augment the company's expertise in neonatology and aerosolized drug delivery. Steven G. Simonson, M.D., has been appointed Senior Vice President and Chief Development Officer, with responsibility for research, clinical development, aerosol device development, regulatory affairs, and patient safety /pharmacovigilance. Dr. Simonson joined Discovery Labs in May 2014 as Vice President, Clinical Development, and brings to Discovery Labs over 25 years of medical practice and pharmaceutical industry clinical trial experience with a significant focus in pulmonary critical care and developing respiratory drugs. The company also announced the appointment of Jan Mazela, M.D., Ph.D. as Special Medical and Scientific Advisor - Neonatology. Dr. Mazela is a pediatrician and neonatologist, a global key opinion leader in neonatology, and an expert in the application of aerosolization technology to neonatal medicine. He currently serves as Medical Director in the Department of Neonatology and Infectious Diseases at Poznan University of Medical Sciences in Poznan, Poland. As part of the organizational changes, Russell G. Clayton, D.O., Discovery Labs' Senior Vice President, Research and Development will be leaving the company by mutual agreement in December 2014 to pursue other interests. He will serve in an advisory role to the company through the planned AEROSURF phase 2 program.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCO:US $1.17 USD +0.02

DSCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.78 USD +0.28
View Industry Companies
 

Industry Analysis

DSCO

Industry Average

Valuation DSCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.6x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DISCOVERY LABORATORIES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.